



# 3-Year Functional Outcomes of Patients With Duchenne Muscular Dystrophy: Pooled Delandistrogene Moxeparovec Clinical Trial Data vs External Controls


Jerry Mendell<sup>1</sup>; Anne M. Connolly<sup>2</sup>; John Day<sup>3</sup>; Craig McDonald<sup>4</sup>; Crystal Proud<sup>5</sup>; Perry Shieh<sup>6</sup>; Craig Zaidman<sup>7</sup>; Matthew Furgerson<sup>1</sup>; Kai Ding<sup>1</sup>; Carol Reid<sup>8</sup>; Alexander P. Murphy<sup>8</sup>; Jacob S. Elkins<sup>1</sup>; Louise Rodino-Klapac<sup>1</sup>

<sup>1</sup>Sarepta Therapeutics, Inc., Cambridge, MA, USA; <sup>2</sup>Chief of Neurology Division, Nationwide Children's Hospital, Columbus, OH, USA, and Professor of Pediatrics at The Ohio State University College of Medicine, Columbus, OH, USA; <sup>3</sup>Professor, of Neurology and Neurological Sciences (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology, Stanford University, Palo Alto, CA, USA; <sup>4</sup>Chair, Department of Physical Medicine & Rehabilitation and Professor, Departments of Pediatrics and Physical Medicine & Rehabilitation, UC Davis, Davis, CA, USA; <sup>5</sup>Pediatric Neurologist and Director of Neurology, Children's Hospital of The King's Daughters, Norfolk, VA, USA; <sup>6</sup>Neurologist, UCLA Health, Los Angeles, CA, USA; <sup>7</sup>Professor of Neurology and of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA; <sup>8</sup>Roche Products Ltd, Welwyn Garden City, UK  
 Presenter


## SUPPLEMENTARY INFORMATION

### Appendix: Changes in NSAA Total Score, RFF Time and Velocity, and 10MWR Time and Velocity (MMRM)


#### NSAA Total Score




#### RFF Time



#### RFF Velocity



#### 10MWR Time



#### 10MWR Velocity

